Direct Answer
Boston Scientific is a global medical device company that makes minimally invasive cardiology, electrophysiology, and endoscopy devices. Its FARAPULSE pulsed field ablation system for atrial fibrillation treatment has been a major market share driver. Revenue comes from both capital equipment placements and the high-volume, recurring disposable supplies consumed in each procedure.
Company snapshot
| Field | Detail |
|---|---|
| Company | Boston Scientific Corporation |
| Ticker | BSX |
| Exchange | NYSE |
| Index | S&P 500, Wilshire 5000 |
| Sector | Health Care |
| Industry | Medical Devices |
| Headquarters | Marlborough, Massachusetts, United States |
| Founded | 1979 |
| Fiscal year end | December 31 |
| SEC CIK | 0000316206 |
What Boston Scientific does
Boston Scientific Corporation is a global developer, manufacturer, and marketer of medical devices used in minimally invasive medical procedures. The company's products treat conditions of the cardiovascular, urological, gastrointestinal, and neurological systems, with a strategic focus on developing less invasive alternatives to open surgery.
Boston Scientific operates through two reportable segments: MedSurg and Cardiovascular.
The MedSurg segment covers endoscopy (endoscopes, biliary, and hemostasis products for gastrointestinal procedures), urology (treatment of urinary incontinence, kidney stones, and benign prostatic hyperplasia), and neuromodulation (spinal cord stimulation for chronic pain and deep brain stimulation for movement disorders).
The Cardiovascular segment covers cardiac rhythm management (implantable defibrillators, cardiac resynchronization therapy devices, pacemakers), electrophysiology (ablation systems, mapping systems, access catheters for cardiac arrhythmia treatment), and interventional cardiology (coronary stents, drug-coated balloons, intravascular imaging). The FARAPULSE pulsed field ablation system is the highest-profile near-term growth driver, addressing the large and growing atrial fibrillation ablation market with a novel energy modality that can complete procedures more quickly than traditional radiofrequency ablation.
Electrophysiology and the FARAPULSE opportunity
Atrial fibrillation affects millions of patients globally and is a leading cause of stroke and heart failure. Catheter ablation has become the preferred treatment for symptom control in patients who fail or cannot tolerate antiarrhythmic drugs. The global EP ablation market has been growing at high single-digit to low double-digit rates, driven by procedure volume growth (more patients receiving ablation), as well as technology upgrades (hospitals transitioning to more capable ablation systems).
FARAPULSE uses pulsed field ablation (PFA), a non-thermal energy modality that applies short, high-voltage electrical pulses to create irreversible electroporation in cardiac tissue. Compared with radiofrequency ablation (RFA), PFA can complete pulmonary vein isolation procedures significantly faster because it is less affected by tissue contact stability; it also has a differentiated safety profile for certain complications (particularly esophageal fistula) because non-cardiac tissues are less susceptible to PFA energy than cardiac myocytes.
FARAPULSE received FDA approval in early 2024 and launched into an extremely receptive market. Boston Scientific's electrophysiology revenue growth accelerated sharply, and the company gained market share from Medtronic's Pulsed Field Ablation programs and from the legacy RFA market. The question for investors is how durable and wide the PFA market share advantage will be as Medtronic and Johnson & Johnson (Biosense Webster) launch competing PFA systems.
Risks and watchlist
- PFA competitive entry: Medtronic and Biosense Webster (J&J) are developing PFA systems. As competitors enter with their own PFA platforms and established customer relationships, Boston Scientific's first-mover advantage in this market will be tested.
- Product liability and recall risk: Implantable devices carry ongoing product liability exposure. A safety signal or major recall on a high-volume product (defibrillator, pacemaker lead, ablation catheter) can create material financial costs and reputational damage.
- Reimbursement pressure: Hospital reimbursement rates for cardiovascular procedures are set by CMS and private payers. Reductions in reimbursement rates reduce hospitals' willingness to adopt new, higher-cost technologies and can compress Boston Scientific's pricing power.
- Procedure volume cyclicality: Elective cardiovascular procedure volumes can slow during economic downturns, hospital staffing shortages, or public health events that redirect hospital capacity.
- Acquisition integration: Boston Scientific has expanded through acquisitions (Acuity Medical, Relievant Medsystems, Apollo Endosurgery, and others). Integrating acquired businesses while maintaining organic growth momentum requires sustained management attention.
Frequently asked questions
What does Boston Scientific do?
Boston Scientific is a global manufacturer of medical devices used in minimally invasive procedures to diagnose and treat a wide range of cardiovascular, cardiac rhythm, and endoscopy-related conditions. The company operates in two reportable segments: MedSurg (endoscopy, urology, and neuromodulation) and Cardiovascular (interventional cardiology, cardiac rhythm management, and electrophysiology). Major product categories include stents and drug-eluting balloons for coronary artery disease, cardiac resynchronization therapy and defibrillator devices, ablation systems for atrial fibrillation treatment, endoscopes and related accessories, and neuromodulation devices for chronic pain.
How does Boston Scientific make money?
Boston Scientific generates revenue by selling medical devices and disposables to hospitals and health systems worldwide. Revenue is broadly divided between capital equipment (imaging systems, ablation generators, endoscopy platforms) and the higher-volume, recurring disposables (catheters, stents, single-use endoscopes, leads, balloons, access sheaths) that accompany those systems. The disposables model creates recurring revenue because every procedure using a Boston Scientific platform consumes single-use supplies. Electrophysiology (atrial fibrillation ablation) and cardiovascular devices are the primary near-term growth drivers, reflecting both procedure volume growth and market share gains from newer technologies.
Why is electrophysiology so important to Boston Scientific's growth?
Electrophysiology (EP) is the treatment of cardiac rhythm disorders including atrial fibrillation through catheter ablation, the process of using energy (radiofrequency, cryotherapy, or pulsed field ablation) to destroy abnormal electrical tissue in the heart. Atrial fibrillation is one of the most common and undertreated cardiac conditions globally, and catheter ablation is increasingly recognized as superior to drug therapy for symptom control and potentially for reducing long-term outcomes. Boston Scientific's FARAPULSE pulsed field ablation (PFA) system entered the market in 2024 and has driven accelerating EP market share gains. PFA is a faster and potentially safer ablation modality that has catalyzed procedure volume growth across the EP market.
How does Boston Scientific compete with Medtronic and Abbott?
Boston Scientific, Medtronic, and Abbott (with Edwards Lifesciences for structural heart) are the three dominant global medical device companies in cardiac intervention. Medtronic is larger across more categories; Abbott is strong in electrophysiology (CardioInsight, TactiCath), structural heart (Tendyne, TriClip), and diabetes. Boston Scientific has differentiated in electrophysiology through FARAPULSE PFA, in coronary intervention through drug-coated balloon technologies, and in endoscopy through single-use endoscope platforms. Competition is product-by-product and procedure-by-procedure rather than company-to-company, as each platform serves a specific clinical workflow.
What are the main risks for Boston Scientific investors to watch?
Key risks include product liability and recall risk (implantable devices carry ongoing product liability exposure; a recall or safety signal on a major product line can create material financial and reputational costs), reimbursement risk (medical device reimbursement rates are set by Medicare and private payers and can be reduced, affecting the economics of both hospitals adopting new technologies and Boston Scientific's pricing power), competitive innovation (rapid product cycles in electrophysiology mean that today's leading platform can be displaced by a competitor's next-generation technology within a few years), procedure volume cyclicality (elective cardiovascular procedure volumes can slow during economic downturns or when hospital staffing constraints limit capacity), and acquisition integration (Boston Scientific has grown partly through acquisitions and must integrate new businesses without disrupting the organic growth engine).